ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis, aiming to keep Xolair sales, pushes successor to ph3
December 10, 2018With blockbuster Xolair aging, Novartis is looking to usher in a successor to protect its sales. And it got one step closer this week. -
Novartis takes Xolair follow-up into phase III hives trial
December 06, 2018Novartis says it intends to move a drug for chronic spontaneous urticaria (CSU), a severe form of hives, into a phase III programme on the strength of a mid-stage study...... -
Xolair deemed ‘breakthrough’ therapy for food allergies
August 15, 2018Roche/Novartis’ Xolair has been awarded breakthrough status in the US for treatment of severe allergic reactions after accidental exposure to foods allergens. -
FDA Grants Breakthrough Therapy Designation for Xolair
August 14, 2018Genentech announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergie -
Novartis’ Xolair backed in global urticaria guidelines
March 07, 2018Novartis’ Xolair has been recommended in global guidelines for treating chronic spontaneous urticaria in patients unresponsive to antihistamines.
Pharma Sources Insight January 2025
